The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

“Treatment decisions for people with major depressive disorder are challenging, particularly for patients who have already not benefitted from one or more medications,” said Michael E. Thase M.D., ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

Myriad hailed Genesight, a pharmaco-genomics (PGx) test for depression drugs, as its entrance into a giant untapped market when they acquired the product. Subsequently the product failed its primary ...

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...

The genetic-testing company Myriad Genetics' biggest up-and-coming product is a test that claims to match patients with depression to the best medications for them, based on their DNA. The test, ...

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...

SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...

Myriad Genetics stock launched to a 10-month high Thursday after UnitedHealth Group (UNH) decided to provide insurance coverage for its genetic testing kit, GeneSight. UnitedHealth will cover genetic ...